Fred T Lee Jr MD

Fred T. Lee Jr, MD is a professor (tenure) of Radiology, Biomedical Engineering, and Urology, and the The Robert A. Turrell Professor of Imaging Science at the University of Wisconsin. He previously served as the Chief of Abdominal Imaging and Intervention, Chief of Oncologic Imaging, and Senior Vice Chair at the University of Wisconsin Department of Radiology. He received his bachelor of arts magna cum laude and medical degrees from the Six-Year Medical Program at Boston University, completed an internship in surgery at the University of Massachusetts, and received his radiology training at the University of Rochester, Rochester, NY. He has been a University of Wisconsin faculty member since 1991, and was designated as a Radiologic Society of North America Scholar in 1996.

While completing the requirements for the RSNA Scholars program, Dr. Lee developed an interest in minimally invasive tumor ablation therapy, leading him to establish the Tumor Ablation Laboratory at the University of Wisconsin in 1995, one of the first of its type in the world. His work has resulted in over 300 scientific publications, hundreds of scientific and business presentations, 20 book chapters, 24 inventions/patents, and substantial federal and industrial grant support. He is the recipient of more than 50 major honors and awards, including the Society of Interventional Radiology Gold Medal, the 2021 Hector F. DeLuca Scientific Achievement Award, the UW Health Presidential Physician Leadership Award, and the Grand Prize in the 2014 Wisconsin Governor’s Business Plan Competition. Dr. Lee is a founding member of the International Working Group on Tumor Ablation, and a founder of three venture-backed biotech start-up companies devoted to cancer treatment: Cellectar, Inc.; Ethicon (J&J) in 2016; and Elucent Medical, Inc. a commercial stage company which manufactures and markets a device for localizing breast cancer and has been used in over 10,000 patients. He is also a former board member and senior advisor to HistoSonics, Inc., and helped lead the translation of histotripsy into a clinical device.